Testing asymptomatic individuals for unsuspected conditions is not new to the medical and 25 public health communities and protocols to develop screening tests are well-established.
ACMG has recently re-emphasized that this set of genes in not appropriate for general 48 screening until their natural history and epidemiology are better understood. 12 
50
In addition, many conditions commonly included in genetic screening tests do not have a 51 reference standard test/confirmatory test. In the context of screening, a confirmatory test 52 adjudicates the presence or absence of a medical condition and should not be confused with an 53 orthogonal analytical confirmation that confirms the presence or absence of a genetic variant.
54
Examples of screening tests and clinical confirmatory tests include mammogram followed by 4
The predictive values provide the post-test probability of disease for an individual. 15 Predictive values address the probability that a person with a positive result actually has the condition than sensitivity and specificity since in practice the presence/absence of disease is unknown 86 prior to testing. 16 The predictive values also help inform the most appropriate cut-off threshold 87 between a positive result and negative result as appropriate for the test's intended use. Sliding 88 the cut-off towards higher specificity will result in fewer false positives, while sliding the cut-off 89 toward higher sensitivity will decrease false negatives. 17 (Figure 1 ) When designing a screening 90 test, the extent to which true positive and true negative results are medically desirable and the 91 extent to which false positive and false negative results are tolerable or even acceptable must 92 be weighed. 2 Considerations include the immediate and long-term burden on the healthcare 93 system, the treatability of the condition, psychosocial effects, and the potential over-utilization of 94 invasive procedures, diagnostic procedures, or surveillance. 1, 2 95 96 Unlike sensitivity and specificity, PPV and NPV will vary depending on the prevalence of the 97 disease in the test population. For tests with very high sensitivity and specificity, the PPV may 98 still be quite low, if the disease prevalence is low. At very low prevalence, small changes in 99 specificity can dramatically reduce the PPV. (Figure 2 ). It is noteworthy that diminishing disease 100 prevalence in a test population adversely impacts PPV more than NPV. When disease 101 prevalence is very low, increasing the specificity will improve the PPV, but have negligible 102 impact on the sensitivity (and NPV). 17, 18 Since sensitivity has a greater influence on NPV and 103 specificity has a greater influence on PPV, screening test discussions focus primarily on PPV 104 and specificity.
106
There are three test design options that will increase the PPV of a screening test: 1) increase 107 the specificity of the screening test, 2) pair the screening test with a clinical confirmatory test, 108 and 3) employ the screening test in a population with a higher disease prevalence. In genetic screening of unselected populations, increasing the specificity of the genetic screening test itself 110 is the most viable option. It is described in detail below.
111

Applying Screening Principles to Genetics
112
The test design terminology used widely in laboratory medicine is not always consistently 113 applied to genetic testing. Table 1 provides general definitions of key assay development terms   114 and examples of these terms applied to genetics. A potential source of confusion stems from 115 the fact that PPV and penetrance both address the probability of phenotypic manifestation, but 116 they address very different probabilities. PPV applies to all types of tests, it is dependent 117 primarily on the test's specificity and disease prevalence in the test population, and it provides 118 information about false positives. In the context of genetics, PPV addresses whether a patient 119 with a positive result has the associated inherited condition, such as HBOC. PPV does not 120 address the penetrance of the condition, the types of cancers that are associated with a given 121 hereditary cancer syndrome, nor the patient's risk of developing one of those cancers. In 122 contrast, penetrance is a feature unique to genetic conditions (not tests) and is only applicable 123 once a positive result is confirmed to be a true positive. Penetrance addresses the chance that 124 a person diagnosed with a genetic condition, such as HBOC, will develop certain kinds of 125 cancers. Uncertain penetrance is another unique challenge in genetic testing. 8, 19, 20 126 127 As mentioned, a significant challenge of genetic test design is the lack of a large "truth set" 128 cohort, established by a reference standard test, that can be used for clinical validation. Ideally, 129 during test development, a large cohort of samples from individuals known to have a genetic 130 condition and large cohort known to be free of the condition would be used to determine clinical 131 sensitivity and specificity of the genetic test. This "truth set" would enable the developer to 132 determine the number of false positive results at different levels of specificity, and then set a 133 cut-off at the desired level. In the absence of a "truth set cohort", clinical validity is estimated 134 from the level of confidence that a specific variant does or does not cause disease. The 135 minimum certainty that a variant causes disease is analogous to the clinical specificity. 18 When testing high-risk individuals, the ACMG/AMP variant classification guideline indicates that 138 an appropriate positive/negative cut-off is when there is at least 90% confidence that a variant is 139 disease-causing. This places the cut-off between variant of uncertain significance (VUS) and 140 likely pathogenic (LP) and triggers the issuance of a positive report when a variant is classified 141 as Pathogenic (P) or Likely Pathogenic (LP) . 21 ( Figure 1B ). Assuming the confidence in 142 pathogenic variants is 100%, the possibility of clinical false positives is reflected in the minimum 143 confidence level of LPs. "Likely pathogenic" implies that there is less than 100% certainty that 144 the variant causes disease. Some LPs will be false positives. If the minimum confidence is set 145 at 90% for LPs, then 1 in 10 LP variants may be false positives, which is a medically appropriate 146 cut-off when testing high-risk patients. However, the guideline warns that applying this same 147 cut-off to an asymptomatic test population may result in an unacceptable number of false 148 positives given that the disease prevalence is much lower in an unselected population. 21
150
Many genetic conditions commonly included in screening panels do not have a clinical 151 confirmatory test. This is especially concerning for conditions where the clinical impact of a false 152 positive is harmful, expensive, or irreversible. Outside of genetics, screening tests are 153 intentionally designed to permit some false positives to avoid missing true positives. These false 154 positives are tolerated because it is standard practice to follow a positive screening test with a 155 more specific confirmatory diagnostic test. 1 For genetic tests that do not have a clinical 156 confirmatory test, this two-step process is not possible, and therefore the specificity of the 157 screening test itself must be high.
159
Lastly, in the absence of prevalence, penetrance, and predictive values it is impossible to 160 determine the health economic benefit of genetic screening. This may impact the willingness of 161 payers to cover downstream preventive interventions. The cost of managing the false positives 162 may outweigh the potential benefits of identifying the true positives. Simply recommending a 163 lifetime of increased cancer surveillance may seem benign, but it has both cost and risk. The 7 more mammograms a woman undergoes, the more likely she will have a false positive result.
165
This will result in unnecessary anxiety and invasive follow-up tests. The chance of a false 166 positive result after one mammogram is 10%. Younger women are more likely to have a false 167 positive result than older women. After 10 yearly mammograms, the chance of having a false 168 positive is 50-60%. 22 Without data to support the safety and efficacy of an intervention, 169 increased screening followed by increased surveillance may do more harm than good. There 
Estimating Specificity, Prevalence, and PPV in Genetic Screening
179
We estimated specificity, prevalence and PPV for autosomal dominant monogenic disorders in 180 asymptomatic individuals in an unselected (low risk) population. The approximate specificity and 181 PPV over a range of disease prevalence are presented in Tables 2 and 3 . They are based on 182 the following assumptions:
183
• 100% analytical test sensitivity.
184
• 100% confidence in a "pathogenic" classification.
185
• 90% confidence in a "likely pathogenic" classification. In practice, the actual confidence will 186 vary by variant type and gene/condition.
187
• ⅓ of all positive results are "likely pathogenic" variants and ⅔ of all positive results are 188 "pathogenic". Together, these compose the "overall positive rate." In practice, this will vary 189 by laboratory and condition. 
195
• Prevalence of ACMG59 TM and other inherited diseases in an unselected population is not 196 known but reasonable estimates range from 1/25,000 for the rarest conditions and 1/500 for 197 the more common conditions. 29-32 Several conditions are so rare that firm epidemiological 198 estimates are not available.
200
The specificity of the test depends on the overall positive rate of the test, the type of variant, the 201 strength of the gene-disease association, and knowledge of the specific gene/disorder. The 202 specificity provided during assay development may not be representative of the test population 203 in terms of disease prevalence. For example, the test cohort may have been comprised of an 204 equal number of samples from patients with disease and patient free of the disease. However, 205 the overall positive rate in practice is not 50%, and therefore the clinical specificity will need to 206 be recalculated. Supplemental Figure 1 provides an example of how the overall positive rate is 207 used to determine the specificities found in Tables 2 and 3. 208 209 Similar to other authors, the calculations in Tables 2 and 3 used the assumption that all LP 210 variants have a confidence level of 90%. 18, 21, 33 In the absence of empirical data obtained from 211 comparison with a reference standard test, 90% is admittedly an estimate of the minimum 212 confidence. In practice, the level of confidence will vary depending on the variant. For a 213 monogenic disorder with a dominant inheritance pattern caused primarily by loss of gene 214 function from simple variants, the specificity of variant classification will generally decrease for 215 each of the following functional categories (highest specificity to lowest specificity): known 216 pathogenic variants, loss-of-function variants in relevant gene domains (nonsense and 217 frameshift variants), canonical splice altering variants and non-canonical splice variants with some functional evidence, missense variants with credible functional evidence. This trend 219 toward decreasing specificity is due to the inherent complexity of interpretation and the rate of 220 errors that can occur in applying evidence toward a classification. Specificity (confidence) will be 221 100% for well-known pathogenic variants. This will decrease to below 90% in categories near 222 the end of the list. As with other types of clinical tests, the positive rate will increase as more 223 genes and variant types are tested or when less stringent criteria are used to specify a variant 224 as "positive." The false positive rate will increase as the overall positive rate increases.
226
In practice, the PPV for likely pathogenic variants should be estimated for each condition shown for ACMG59 TM conditions in order to demonstrate that higher overall positive rates will 231 lower the PPV. (Table 2 ). Note that specificity decreases as the number of LPs increase and as 232 panel size increases and, as noted above, small changes in specificity can have a significant 233 impact on PPV when testing for diseases with a low prevalence. Importantly, most conditions 234 included in genetic screening panels have a very low prevalence in an unselected population, 235 and thus may have a corresponding low PPV for LP variants if specificity is not adjusted.
237
When the prevalence is very low, the false positive rate for a test is greater than the prevalence 238 of the condition. This is known as the False Positive Paradox. 34, 35 Under these conditions, more 239 disease-free individuals will test positive than affected individuals. If the ACMG59 TM screening 240 test has a 99.9% specificity then the test will find more false positives than true positives for 241 those conditions with a prevalence of 1/1,000 or less. 36 Conditions with a disease prevalence of 242 1/25,000 will always generate more false positive LPs than true positives, since it would require 243 a specificity of greater than 99.995% to obtain one true positive for each false positive. 18 37
245 Recommendations for Genetic Screening Test Design and Reporting
As an alternative to estimates of PPV, we considered whether PPV could be extrapolated from 247 intra-laboratory reclassification rates, published reclassification rates from high volume 248 laboratories, or the reclassification rate in public variant databases. We concluded that none of 249 these are a replacement for condition-specific performance metrics derived from comparison 250 with a clinical "truth set." Datasets from high volume laboratories indicate that reclassification 251 rates are laboratory dependent, based on high-risk populations, and fluctuate with differences in 252 test volume in each year, the rate at which new data appears that affect classes of variants, and 253 how many genes were available for testing each year. 38 
270
We considered three possible options for increasing the specificity of a genetic screening test.
271
The laboratory could chose to report only known pathogenic variants as a positive result (100% 
294
Two different strategies have been proposed to adjust the specificity of a genetic test according 295 to intended use: 1) adjust the cut-off between positive and negative, 6 or 2) adjust the stringency 296 of variant classification. 21 18,41 We recommend following the protocol used for other types of 297 clinical tests and simply adjust the positive/negative cut-off as appropriate for the intended use.
298
Variant classification itself should remain indifferent to the intended use. Figure 1B shows how 299 setting the cut off between lower and higher confidence LPs can reduce the false positive rate to 300 an acceptable level for a screening test. It is important to realize that the impact of this approach 301 on clinical sensitivity will be negligible given the low prevalence of these conditions. Including lower confidence novel variants that inherently reduce the specificity of the screening test is of 303 little benefit to the patient. 17 
317
• For screening tests, describe the clinical features of the syndrome and the penetrance of each 318 feature in an unselected population, if known, or state that it is not known.
319
• Provide a reference to patient management guidelines that have been proven safe and effective 320 in the test population, if available, or state that none exist.
321
• Participants should be aware that post-test preventive care may not be covered by insurance.
322
Coverage will depend on the level of evidence for the utility of the intervention and the type of 
363
• Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), likely pathogenic variant in 364 DSP. The prevalence is approximately 1/5000 46 and the PPV is estimated to be less than 17%.
365
The studies conducted on an unselected population suggest that the penetrance is very low. 10
366
There is no definitive diagnostic standard. No guidelines exist detailing the best management or 367 counseling for this patient. Increased surveillance has not been demonstrated to be safe, useful, 368 or cost-effective. Insurance coverage for increased surveillance may be challenged. In addition, 369 one of the key risk management recommendations -limiting exercise -runs counter to physical 370 activity recommendations known to be beneficial for a wide range of health conditions.
371
• Familial Hypercholesterolemia (FH) likely pathogenic variant in LDLR. The prevalence of 372 FH in an unselected population is approximately 1/220. 28, 47, 48 The estimated PPV is 373 approximately 90%. A functional study, such as LDL cholesterol level, can help adjudicate 374 whether this is a true positive or a false positive. Since the penetrance of FH has been 375 determined to be approximately the same in high risk and unselected cohorts, it is appropriate 376 to manage confirmed cases according to FH guidelines. 49 The presence of a positive genetic 377 test result alone meets criteria for most commercial insurance coverage policies for the 378 preventive management of FH. 
530
Tests intended for higher risk populations (diagnostic testing) may tolerate more false positives 531 than tests intended for low-risk populations (screening).
533
Generic definitions Genetics example
Analytical validity
The test accurately detects the analyte when it is present (analytical sensitivity) and does not detect it when it is absent (analytical specificity).
Confirm by orthogonal technology during development phase.
The test accurately detects a sequence variant in BRCA1 when it is present and does not detect it when it is absent.
Confirm by orthogonal technology until performance metrics are well-established.
Clinical validity
The test accurately detects the disease when it is known to be present and does not detect it when it is known to be absent.
A reference standard test is used to identify samples known to have the condition and those known to be free of the condition. to the a priori probability that a subject selected at random from the test population has the condition. 
572
has been set to allow for 1/10 LP positives to be a false positive; thus 1/30 positives are false positives.
581
Therefore, 5 of the positive results are false positives. and test specificity = 2850/(2850+5) = 99.82%.
582
This method is used to calculate specificities for Tables 2 and 3 for varying positive test rates.   583   584  585  586 
